Exchanges in the 'a' determinant of the hepatitis B virus surface antigen revisited.

HBsAg antigenicity HBsAg mutants Hepatitis B virus S protein ‘a’ determinant

Journal

Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 16 04 2024
revised: 02 07 2024
accepted: 17 07 2024
medline: 11 8 2024
pubmed: 11 8 2024
entrez: 10 8 2024
Statut: aheadofprint

Résumé

The hepatitis B virus surface antigen's (HBsAg) 'a' determinant comprises a sequence of amino acid residues located in the major hydrophilic region of the S protein, whose exchanges are closely associated with compromising the antigenicity and immunogenicity of that antigen. The HBsAg is generally present in the bloodstream of individuals with acute or chronic hepatitis B virus (HBV) infection. It is classically known as the HBV infection marker, and is therefore the first marker to be investigated in the laboratory in the clinical hypothesis of infection by this agent. One of the factors that compromises the HBsAg detection in the bloodstream by the assays adopted in serological screening in both clinical contexts is the loss of S protein antigenicity. This can occur due to mutations that emerge in the HBV genome regions that encode the S protein, especially for its immunodominant region - the 'a' determinant. These mutations can induce exchanges of amino acid residues in the S protein's primary structure, altering its tertiary structure and the antigenic conformation, which may not be recognized by anti-HBs antibodies, compromising the infection diagnosis. In addition, these exchanges can render ineffective the anti-HBs antibodies action acquired by vaccination, compromise the effectiveness of the chronically HBV infected patient's treatment, and also the HBsAg immunogenicity, by promoting its retention within the cell. In this review, the residues exchange that alter the S protein's structure is revisited, as well as the mechanisms that lead to the HBsAg antigenicity loss, and the clinical, laboratory and epidemiological consequences of this phenomenon.

Identifiants

pubmed: 39127000
pii: S0042-6822(24)00205-8
doi: 10.1016/j.virol.2024.110184
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

110184

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there are no competing interests (financial or non-financial) related to the content of the specific article. The authors further state that this article is a review article and that, for its compilation, research involving human participants and/or animals was not necessary.

Auteurs

Robério Amorim de Almeida Pondé (RAA)

Secretaria de Estado da Saúde -SES/Superintendência de Vigilância Em Saúde-SUVISA/GO, Gerência de Vigilância Epidemiológica de Doenças Transmissíveis-GVEDT/Coordenação de Análises e Pesquisas-CAP, Goiânia, Goiás, Brazil; Laboratory of Human Virology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil. Electronic address: roponde@gmail.com.

Guilherme de Sousa Pondé Amorim (GSP)

Evangelical University of Goiás, Faculty of Medicine, Anápolis, Goiás, Brazil.

Classifications MeSH